List of investigational long COVID drugs

Last updated

This is a list of investigational long COVID drugs, or drugs that are currently under development for clinical use for the treatment of post-acute COVID-19 syndrome (long COVID) but are not yet approved.

Contents

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]".

This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

Under development

Phase 2/3

Phase 2

Preclinical

Research

Clinical phase unknown

Not under development

Discontinued

Clinically used drugs

Approved drugs

Off-label drugs

See also

References

  1. 1 2 3 4 5 Seo JW, Kim SE, Kim Y, Kim EJ, Kim T, Kim T, Lee SH, Lee E, Lee J, Seo YB, Jeong YH, Jung YH, Choi YJ, Song JY (March 2024). "Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID". Infect Chemother. 56 (1): 122–157. doi:10.3947/ic.2024.0024. PMC   10990882 . PMID   38527781.
  2. 1 2 3 4 5 6 7 8 Munipalli, Bala; Dawson, Nancy L.; Rosales, Juan C. Cardenas; Paul, Stefan N.; Delaney, Troy R.; Morris, Anjali M.; Brigham, Tara J.; Robinson, Arden R.; Dabrh, Abd Moain Abu (14 April 2025). "Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review". SN Comprehensive Clinical Medicine. 7 (1) 82. doi:10.1007/s42399-025-01837-z. ISSN   2523-8973 . Retrieved 17 September 2025.
  3. Kondo T, Higa R, Kuniba M, Shinzato H, Takaesu Y (September 2024). "Successful treatment with guanfacine in a long-COVID case manifesting marked cognitive impairment". Neuropsychopharmacol Rep. 44 (3): 585–590. doi:10.1002/npr2.12466. PMC   11544435 . PMID   38934345.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Ivlev I, Wagner J, Phillips T, Treadwell JR (July 2025). "Interventions for Long COVID: A Narrative Review". J Gen Intern Med. 40 (9): 2005–2023. doi:10.1007/s11606-024-09254-z. PMC  12325819. PMID   39984803.
  5. 1 2 Hashimoto K (2023). "Overview of the potential use of fluvoxamine for COVID-19 and long COVID". Discov Ment Health. 3 (1) 9. doi:10.1007/s44192-023-00036-3. PMC   10029802 . PMID   36968793.
  6. German ER, Jairath MK, Caston J (April 2023). "Treatment of Long-Haul COVID Patients With Off-Label Acyclovir". Cureus. 15 (4) e37926. doi: 10.7759/cureus.37926 . PMC   10205150 . PMID   37228547.
  7. Yavropoulou MP, Tsokos GC, Chrousos GP, Sfikakis PP (December 2022). "Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID". Clin Immunol. 245 109133. doi:10.1016/j.clim.2022.109133. PMC   9519365 . PMID   36182048.
  8. Ramonfaur D, Ayad N, Liu PH, Zhou J, Wu Y, Li J, Chen G (September 2024). "The global clinical studies of long COVID". Int J Infect Dis. 146 107105. doi:10.1016/j.ijid.2024.107105. PMID   38782355.
  9. 1 2 Griffin DO (September 2024). "Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach". Open Forum Infect Dis. 11 (9) ofae462. doi:10.1093/ofid/ofae462. PMC   11363684 . PMID   39220656.
  10. Low ZX, Yong SJ, Alrasheed HA, Al-Subaie MF, Al Kaabi NA, Alfaresi M, Albayat H, Alotaibi J, Al Bshabshe A, Alwashmi AS, Sabour AA, Alshiekheid MA, Almansour ZH, Alharthi H, Al Ali HA, Almoumen AA, Alqasimi NA, AlSaihati H, Rodriguez-Morales AJ, Rabaan AA (March 2025). "Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review". Prog Neuropsychopharmacol Biol Psychiatry. 137 111279. doi:10.1016/j.pnpbp.2025.111279. PMID   39909170.
  11. Bobak L, Dorney I, Kovacevich A, Barnett BS (March 2025). "Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation". J Psychoactive Drugs: 1–9. doi:10.1080/02791072.2025.2478097. PMID   40084630.
  12. 1 2 3 Lee, Elliott K; Auger, R. Robert (23 April 2024). "Sleep and Long COVID—A Review and Exploration of Sleep Disturbances in Post Acute Sequelae of SARS-COV-2 (PASC) and Therapeutic Possibilities". Current Sleep Medicine Reports. 10 (2): 169–180. doi:10.1007/s40675-024-00299-4. ISSN   2198-6401 . Retrieved 17 September 2025.
  13. Koonce RM, Martin BC (January 2024). "The association between suspected long-COVID and stimulant prescribing in the United States". Psychiatry Res. 331 115686. doi:10.1016/j.psychres.2023.115686. PMC   10797645 . PMID   38142603.
  14. Vaziri-Harami R, Delkash P (January 2022). "Can l-carnitine reduce post-COVID-19 fatigue?". Ann Med Surg (Lond). 73 103145. doi:10.1016/j.amsu.2021.103145. PMC   8667465 . PMID   34925826.
  15. Pliszka, Andrew G. (28 June 2022). "Modafinil: A Review and Its Potential Use in the Treatment of Long COVID Fatigue and Neurocognitive Deficits". American Journal of Psychiatry Residents' Journal. 17 (4): 5–7. doi: 10.1176/appi.ajp-rj.2022.170402 . ISSN   2474-4662.